Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

Background: Immune checkpoint inhibitors (ICIs) have shown clinical benefit in many advanced tumors, however, pseudo-progression is a noted phenomenon of ICIs characterized by radiologic enlargement of the tumor burden, followed by regression. How to differentiate pseudo-progression from progression...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Med (Lausanne)
Egile Nagusiak: Li, Hui, Zhou, Xin, Zhang, Ding, Wang, Guoqiang, Cheng, Xiaochun, Xu, Caihong, Yao, Bin, Pang, Linrong, Chen, Jun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Medicine
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7399050/
https://ncbi.nlm.nih.gov/pubmed/32850889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.00366
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak